CHROMATIN LICENSES GENE STACKING TECHNOLOGY TO SYGENTA BIOTECHNOLOGY, INC.
Chromatin Inc. announced today that it has entered into a research and commercial license agreement with Syngenta Biotechnology Inc. for Chromatin’s proprietary gene stacking technology.
Chromatin has developed a novel approach to gene stacking, using the plant’s own DNA to deliver several genes on a mini-chromosome. Under the agreement, Syngenta has obtained non-exclusive rights to use Chromatin’s gene stacking technology for trait genes in corn and soybeans.
“Growers need increasingly more sophisticated tools to meet the demands on the agriculture market, and stacked traits along with improved seed germplasm will be instrumental,” said Roger Kemble, Head of Syngenta Crop Genetics Research. “We will evaluate this technology in combination with our own innovative research programs and strong pipeline as part of our intense commitment to speed delivery of products to market.”
“Syngenta is a leading agribusiness company committed to developing crops that meet multiple needs. Chromatin is pleased to partner with Syngenta, whose trait gene inventory and crop production programs make them an ideal partner for us,” said Daphne Preuss, Chromatin’s Chief Scientific Officer and President.
Further terms of the deal were not disclosed.
About Chromatin:
Chromatin, Inc. develops and markets novel proprietary technology that enables entire chromosomes to be designed and incorporated into plant cells. These mini-chromosomes can be used in any plant to simultaneously introduce multiple genes while maintaining precise control of gene expression. Chromatin’s mini-chromosome technology can be used to deliver genes that benefit the agricultural, nutritional, energy, pharmaceutical, and chemical sectors.